{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03157804",
      "OrgStudyIdInfo": {
        "OrgStudyId": "2011-006100-12"
      },
      "Organization": {
        "OrgFullName": "Hospital Infantil Universitario Niño Jesús, Madrid, Spain",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A",
      "OfficialTitle": "Clinical Trial Phase I / II to Evaluate the Safety and Efficacy of the Infusion of Autologous CD34 + Cells Transduced With a Lentiviral Vector Carrying the Gene FANCA in Patients With FA Subtype A (FANCOLEN-1)",
      "Acronym": "FANCOLEN-1"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2020",
      "OverallStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "January 7, 2016",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "April 23, 2019",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "April 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "April 26, 2017",
      "StudyFirstSubmitQCDate": "May 16, 2017",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "May 17, 2017",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "November 23, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 25, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Julian Sevilla",
        "ResponsiblePartyInvestigatorTitle": "M.D.PhD Specialist in Hematology Hemotherapy, Responsible for the Transfusion Service and Unit for the Obtention and Processing of Hematopoietic Progenitors and other cellular therapies at the Hospital Infantil Universitario Niño Jesús de Madrid.",
        "ResponsiblePartyInvestigatorAffiliation": "Hospital Infantil Universitario Niño Jesús, Madrid, Spain"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Hospital Infantil Universitario Niño Jesús, Madrid, Spain",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Centro de Investigación en Red de Enfermedades Raras (CIBERER)",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Hospital Vall d'Hebron",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Universitat Autonoma de Barcelona",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {},
    "DescriptionModule": {
      "BriefSummary": "This is an open, Phase I / II clinical trial to evaluate the safety and efficacy of a hematopoietic gene therapy procedure with an orphan drug consisting of a lentiviral vector carrying the FANCA gene for patients with Fanconi Anemia of Subtype A .\n\nCD34 + cells derived from bone marrow and / or mobilized peripheral blood (fresh and / or cryopreserved) from patients with Fanconi subtype A (FA-A), will be transduced ex vivo with a lentiviral vector carrying the gene FANCA (orphan drug) . After transduction the cells will be inoculated in patients in order to restore their hematopoiesis with genetically corrected stem cells.",
      "DetailedDescription": "The main objective of this open-label Phase I / II clinical trial is to evaluate the safety and therapeutic efficacy of a hematopoietic gene therapy procedure with an orphan drug consisting of a lentiviral vector carrying the FANCA gene for patients with Fanconi's Anemia Subtype A.\n\nThe drug to be administered to the patients consists of the cellular product resulting from the transduction of autologous CD34 + cells with the therapeutic lentiviral vector PGK-FANCA.Wpre *.\n\nThe dose of cells to infuse in the patients will be that obtained from the transduction process of between 3x10^5 and 4x10^6 CD34 + cells / kg of patient body weight.\n\nThe cells will be infused intravenously in a single dose, after complete the transduction process.\n\nFollow-up period: 3 years after infusion of transduced cells. However, patients will be monitored outside the clinical trial over a 10-year period.\n\nFollow-up of the grafted transduced cells will be performed on peripheral blood and bone marrow samples."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Fanconi Anemia"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "9",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Autologous CD34+ cells transducted with PGK-FANCA-Wpre *",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "CD34 + cells from patients with Fanconi subtype A (FA-A) transduced ex vivo with lentiviral vector carrying the gene FANCA, PGK-FANCA-Wpre*The product to be infused consist of a suspension of transduced CD34^+ cells.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Procedure: IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)",
                "Biological: Genetically Engineered Hematopoietic Stem/Progenitor Cells",
                "Other: Laboratory Biomarker Analysis",
                "Biological: Filgrastim",
                "Drug: Plerixafor",
                "Procedure: Bone Marrow Aspiration"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Procedure",
            "InterventionName": "IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Autologous CD34+ cells transducted with PGK-FANCA-Wpre *"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "Genetically Engineered Hematopoietic Stem/Progenitor Cells",
            "InterventionDescription": "Undergo infusion of genetically modified hematopoietic progenitor cell therapy",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Autologous CD34+ cells transducted with PGK-FANCA-Wpre *"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Genetically Engineered HSPCs"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "Laboratory Biomarker Analysis",
            "InterventionDescription": "Correlative studies",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Autologous CD34+ cells transducted with PGK-FANCA-Wpre *"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "Filgrastim",
            "InterventionDescription": "Given subcutaneously (SC)",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Autologous CD34+ cells transducted with PGK-FANCA-Wpre *"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Filgrastim XM02, Filgrastim-sndz, G-CSF (Colony Stimulating Factor), Neupogen, r-metHug-CSF, Recombinant Methionyl Human Granulocyte CSF, rG-CSF, Tbo-filgrastim, Zarxio"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Plerixafor",
            "InterventionDescription": "Given SC",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Autologous CD34+ cells transducted with PGK-FANCA-Wpre *"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "AMD 3100, JM-3100, Mozobil, SDZ SID 791"
              ]
            }
          },
          {
            "InterventionType": "Procedure",
            "InterventionName": "Bone Marrow Aspiration",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Autologous CD34+ cells transducted with PGK-FANCA-Wpre *"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of participants with treatment-related adverse events as assessed by CTCAE v4.0",
            "PrimaryOutcomeDescription": "All adverse events will be registered for 3 years from infusion of transduced cells",
            "PrimaryOutcomeTimeFrame": "Up to 3 years after infusion of transduced cells"
          },
          {
            "PrimaryOutcomeMeasure": "Proportion of patients with at least 0.1 copy of the therapeutic vector per nucleated bone marrow or peripheral blood cells three years after infusion.",
            "PrimaryOutcomeDescription": "Detection of at least 0.1 copy of the therapeutic vector per nucleated bone marrow cell or peripheral blood cells three years after infusion.",
            "PrimaryOutcomeTimeFrame": "3 years after infusion of transduced cells"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Proportion of patients with clinical hematological response after the infusion of autologous CD34 + cells transduced with the therapeutic lentiviral vector",
            "SecondaryOutcomeDescription": "Proportion of patients with clinical hematological response (improvement of cell blood counts at least in one hematological lineage).",
            "SecondaryOutcomeTimeFrame": "3 years after infusion of transduced cells"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPatients diagnosed with Fanconi Anemia complementation group A (FA-A)\nMinimum age 1 year\nMaximum age 21 years\nLansky Index> 60%.\nInformed consent in accordance with current legal regulations.\nNumber of cells to be transduced: At least 3x10^5 purified CD34+ / kg body weight.\nNegative result in the urine pregnancy test at the baseline visit for women of childbearing age, who should be committed to using an effective contraceptive method during the period of study participation.\n\nExclusion Criteria:\n\nPatients with an human leukocyte antigen (HLA) identical family donor.\nEvidence of myelodysplastic syndrome or leukemia, or cytogenetic abnormalities predicting the same in bone marrow aspirates. In this case, the studies carried out two months in advance of the patient's entry into the clinical trial will be considered valid.\nEvidence that the patient to be infused has signs of somatic mosaicism, with hematologic improvement.\nAny illness or concomitant process that in the opinion of the investigator incapacitates the subject for their participation in the study.\nPre-existing sensory or motor impairment> = grade 2 according to the National Cancer Institute (NCl) criteria.\nPregnant or lactating women.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "1 Year",
      "MaximumAge": "21 Years",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Juan A Bueren",
            "OverallOfficialAffiliation": "CIEMAT/CIBERER/IIS.FJD",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Hospital Vall d'Hebron",
            "LocationCity": "Barcelona",
            "LocationZip": "08035",
            "LocationCountry": "Spain"
          },
          {
            "LocationFacility": "Hospital Infantil del Niño Jesus",
            "LocationCity": "Madrid",
            "LocationZip": "28009",
            "LocationCountry": "Spain"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "28103787",
            "ReferenceType": "background",
            "ReferenceCitation": "Adair JE, Sevilla J, Heredia CD, Becker PS, Kiem HP, Bueren J. Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia. Curr Gene Ther. 2017;16(5):338-348. doi: 10.2174/1566523217666170119113029. Review."
          },
          {
            "ReferencePMID": "26415575",
            "ReferenceType": "background",
            "ReferenceCitation": "Molina-Estevez FJ, Nowrouzi A, Lozano ML, Galy A, Charrier S, von Kalle C, Guenechea G, Bueren JA, Schmidt M. Lentiviral-Mediated Gene Therapy in Fanconi Anemia-A Mice Reveals Long-Term Engraftment and Continuous Turnover of Corrected HSCs. Curr Gene Ther. 2015;15(6):550-62."
          },
          {
            "ReferencePMID": "20001454",
            "ReferenceType": "background",
            "ReferenceCitation": "González-Murillo A, Lozano ML, Alvarez L, Jacome A, Almarza E, Navarro S, Segovia JC, Hanenberg H, Guenechea G, Bueren JA, Río P. Development of lentiviral vectors with optimized transcriptional activity for the gene therapy of patients with Fanconi anemia. Hum Gene Ther. 2010 May;21(5):623-30. doi: 10.1089/hum.2009.141."
          },
          {
            "ReferencePMID": "19277017",
            "ReferenceType": "background",
            "ReferenceCitation": "Jacome A, Navarro S, Río P, Yañez RM, González-Murillo A, Lozano ML, Lamana ML, Sevilla J, Olive T, Diaz-Heredia C, Badell I, Estella J, Madero L, Guenechea G, Casado J, Segovia JC, Bueren JA. Lentiviral-mediated genetic correction of hematopoietic and mesenchymal progenitor cells from Fanconi anemia patients. Mol Ther. 2009 Jun;17(6):1083-92. doi: 10.1038/mt.2009.26. Epub 2009 Mar 10."
          },
          {
            "ReferencePMID": "28801449",
            "ReferenceType": "background",
            "ReferenceCitation": "Río P, Navarro S, Guenechea G, Sánchez-Domínguez R, Lamana ML, Yañez R, Casado JA, Mehta PA, Pujol MR, Surrallés J, Charrier S, Galy A, Segovia JC, Díaz de Heredia C, Sevilla J, Bueren JA. Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34(+) cells from Fanconi anemia patients. Blood. 2017 Sep 28;130(13):1535-1542. doi: 10.1182/blood-2017-03-774174. Epub 2017 Aug 11."
          },
          {
            "ReferencePMID": "31501599",
            "ReferenceType": "result",
            "ReferenceCitation": "Río P, Navarro S, Wang W, Sánchez-Domínguez R, Pujol RM, Segovia JC, Bogliolo M, Merino E, Wu N, Salgado R, Lamana ML, Yañez RM, Casado JA, Giménez Y, Román-Rodríguez FJ, Álvarez L, Alberquilla O, Raimbault A, Guenechea G, Lozano ML, Cerrato L, Hernando M, Gálvez E, Hladun R, Giralt I, Barquinero J, Galy A, García de Andoín N, López R, Catalá A, Schwartz JD, Surrallés J, Soulier J, Schmidt M, Díaz de Heredia C, Sevilla J, Bueren JA. Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia. Nat Med. 2019 Sep;25(9):1396-1401. doi: 10.1038/s41591-019-0550-z. Epub 2019 Sep 9."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000005198",
            "ConditionMeshTerm": "Fanconi Syndrome"
          },
          {
            "ConditionMeshId": "D000000740",
            "ConditionMeshTerm": "Anemia"
          },
          {
            "ConditionMeshId": "D000005199",
            "ConditionMeshTerm": "Fanconi Anemia"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000006402",
            "ConditionAncestorTerm": "Hematologic Diseases"
          },
          {
            "ConditionAncestorId": "D000029502",
            "ConditionAncestorTerm": "Anemia, Hypoplastic, Congenital"
          },
          {
            "ConditionAncestorId": "D000000741",
            "ConditionAncestorTerm": "Anemia, Aplastic"
          },
          {
            "ConditionAncestorId": "D000080984",
            "ConditionAncestorTerm": "Congenital Bone Marrow Failure Syndromes"
          },
          {
            "ConditionAncestorId": "D000080983",
            "ConditionAncestorTerm": "Bone Marrow Failure Disorders"
          },
          {
            "ConditionAncestorId": "D000001855",
            "ConditionAncestorTerm": "Bone Marrow Diseases"
          },
          {
            "ConditionAncestorId": "D000030342",
            "ConditionAncestorTerm": "Genetic Diseases, Inborn"
          },
          {
            "ConditionAncestorId": "D000049914",
            "ConditionAncestorTerm": "DNA Repair-Deficiency Disorders"
          },
          {
            "ConditionAncestorId": "D000008659",
            "ConditionAncestorTerm": "Metabolic Diseases"
          },
          {
            "ConditionAncestorId": "D000015499",
            "ConditionAncestorTerm": "Renal Tubular Transport, Inborn Errors"
          },
          {
            "ConditionAncestorId": "D000007674",
            "ConditionAncestorTerm": "Kidney Diseases"
          },
          {
            "ConditionAncestorId": "D000014570",
            "ConditionAncestorTerm": "Urologic Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M3222",
            "ConditionBrowseLeafName": "Anemia",
            "ConditionBrowseLeafAsFound": "Anemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M7493",
            "ConditionBrowseLeafName": "Fanconi Syndrome",
            "ConditionBrowseLeafAsFound": "Fanconi Anemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M7494",
            "ConditionBrowseLeafName": "Fanconi Anemia",
            "ConditionBrowseLeafAsFound": "Fanconi Anemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M15507",
            "ConditionBrowseLeafName": "Syndrome",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8642",
            "ConditionBrowseLeafName": "Hematologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M22608",
            "ConditionBrowseLeafName": "Anemia, Hypoplastic, Congenital",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3223",
            "ConditionBrowseLeafName": "Anemia, Aplastic",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M2241",
            "ConditionBrowseLeafName": "Bone Marrow Failure Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M12270",
            "ConditionBrowseLeafName": "Pancytopenia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M2242",
            "ConditionBrowseLeafName": "Congenital Bone Marrow Failure Syndromes",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4286",
            "ConditionBrowseLeafName": "Bone Marrow Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M22839",
            "ConditionBrowseLeafName": "Genetic Diseases, Inborn",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M25284",
            "ConditionBrowseLeafName": "DNA Repair-Deficiency Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10791",
            "ConditionBrowseLeafName": "Metabolic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M17303",
            "ConditionBrowseLeafName": "Renal Tubular Transport, Inborn Errors",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9850",
            "ConditionBrowseLeafName": "Kidney Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16471",
            "ConditionBrowseLeafName": "Urologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2270",
            "ConditionBrowseLeafName": "Fanconi Anemia",
            "ConditionBrowseLeafAsFound": "Fanconi Anemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T1464",
            "ConditionBrowseLeafName": "Congenital Aplastic Anemia",
            "ConditionBrowseLeafAsFound": "Fanconi Anemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T2272",
            "ConditionBrowseLeafName": "Fanconi Syndrome",
            "ConditionBrowseLeafAsFound": "Fanconi Anemia",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC15",
            "ConditionBrowseBranchName": "Blood and Lymph Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC16",
            "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "C000088327",
            "InterventionMeshTerm": "Plerixafor"
          },
          {
            "InterventionMeshId": "D000078224",
            "InterventionMeshTerm": "Lenograstim"
          },
          {
            "InterventionMeshId": "C000081222",
            "InterventionMeshTerm": "Sargramostim"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000000276",
            "InterventionAncestorTerm": "Adjuvants, Immunologic"
          },
          {
            "InterventionAncestorId": "D000007155",
            "InterventionAncestorTerm": "Immunologic Factors"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          },
          {
            "InterventionAncestorId": "D000019380",
            "InterventionAncestorTerm": "Anti-HIV Agents"
          },
          {
            "InterventionAncestorId": "D000044966",
            "InterventionAncestorTerm": "Anti-Retroviral Agents"
          },
          {
            "InterventionAncestorId": "D000000998",
            "InterventionAncestorTerm": "Antiviral Agents"
          },
          {
            "InterventionAncestorId": "D000000890",
            "InterventionAncestorTerm": "Anti-Infective Agents"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M244297",
            "InterventionBrowseLeafName": "Sargramostim",
            "InterventionBrowseLeafAsFound": "Electrodes",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M340910",
            "InterventionBrowseLeafName": "Plerixafor",
            "InterventionBrowseLeafAsFound": "Prone",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M1945",
            "InterventionBrowseLeafName": "Lenograstim",
            "InterventionBrowseLeafAsFound": "Vitamin",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M257523",
            "InterventionBrowseLeafName": "Molgramostim",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M2780",
            "InterventionBrowseLeafName": "Adjuvants, Immunologic",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9353",
            "InterventionBrowseLeafName": "Immunologic Factors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M20503",
            "InterventionBrowseLeafName": "Anti-HIV Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M24581",
            "InterventionBrowseLeafName": "Anti-Retroviral Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3466",
            "InterventionBrowseLeafName": "Antiviral Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3366",
            "InterventionBrowseLeafName": "Anti-Infective Agents",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          }
        ]
      }
    }
  }
}